AddLife buys Portuguese surgical distributor MoonSurge to deepen Iberian push
What's the deal? Sweden's AddLifeDealroom has a profile for this one. Try Dealroom → has acquired MoonSurge, a Portuguese distributor of medical devices for advanced surgery, for an undisclosed sum. The deal, which closed on November 2, 2026, folds MoonSurge in as an independent subsidiary of MBA Surgical EmpowermentDealroom has a profile for this one. Try Dealroom →, part of AddLife's Medtech division.
What each side brings: MoonSurge supplies surgical solutions in general surgery, urology, gynaecology, and cardiac surgery, with a focus on minimally invasive procedures. It has 14 employees and roughly €5 million in annual revenue, sourcing technologies from European manufacturers. AddLife is a Stockholm-listed life science group with about 85 subsidiaries, over 2,000 staff, and net revenues above US$1.21B.
Why now? AddLife has stepped up dealmaking after a stretch focused on operational improvement. By its Q3 2026 report, it had completed three acquisitions this year and agreed a fourth, with the additions expected to add about US$42.3M in annual sales.
The expansion angle: MoonSurge extends MBA Surgical Empowerment, which already operates in Spain and Portugal, letting AddLife lean on its Spanish subsidiary's infrastructure and relationships across the Iberian market. It follows AddLife's March purchase of UK surgical distributor BioSpectrumDealroom has a profile for this one. Try Dealroom →, part of a broader move into specialist surgical niches.
What's the endgame? The acquisition fits AddLife's stated strategy to grow in "attractive, advanced product segments with long-term growth potential." The company said it was "delighted" to add MoonSurge, which strengthens its advanced surgical offering.
What could go wrong? The near-term financial upside is limited. AddLife expects only a marginal positive contribution to earnings per share this year, and with no price disclosed, the deal's value is chiefly strategic rather than a financial step-change.
The signal: The deal points to continued consolidation among specialist surgical distributors in Southern Europe, as larger groups buy up regional networks to secure commercial channels and build scale in high-margin niches.
Read more: globenewsinfo.com
Image credit: NavyMedicine
